Evotec/$EVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Ticker
$EVO
Sector
Primary listing
Employees
4,759
Headquarters
Website
Evotec Metrics
BasicAdvanced
$1.2B
-
-$1.03
1.06
-
Price and volume
Market cap
$1.2B
Beta
1.06
52-week high
$5.48
52-week low
$2.84
Average daily volume
47K
Financial strength
Current ratio
1.577
Quick ratio
1.348
Long term debt to equity
41.998
Total debt to equity
54.633
Interest coverage (TTM)
-4.97%
Profitability
EBITDA (TTM)
9.546
Gross margin (TTM)
12.89%
Net profit margin (TTM)
-20.01%
Operating margin (TTM)
-9.39%
Effective tax rate (TTM)
-14.35%
Revenue per employee (TTM)
$187,720
Management effectiveness
Return on assets (TTM)
-2.40%
Return on equity (TTM)
-16.75%
Valuation
Price to revenue (TTM)
0.675
Price to book
1.22
Price to tangible book (TTM)
1.91
Price to free cash flow (TTM)
42.152
Free cash flow yield (TTM)
2.37%
Free cash flow per share (TTM)
0.082
Growth
Revenue change (TTM)
-1.41%
Earnings per share change (TTM)
-8.67%
3-year revenue growth (CAGR)
4.38%
10-year revenue growth (CAGR)
22.24%
3-year earnings per share growth (CAGR)
354.98%
10-year earnings per share growth (CAGR)
26.53%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Bulls say / Bears say
Just – Evotec Biologics delivered robust 16% revenue growth to €102.2 m in H1 2025, driven by a broadened customer base beyond traditional partners (Evotec)
Evotec secured US$75 m in performance-based payments from Bristol Myers Squibb for advances in targeted protein degradation and US$20 m for neuroscience collaboration, bolstering near-term cash flow (Evotec)
The non-binding agreement to sell the J.POD biologics manufacturing facility in Toulouse for approximately US$300 m underpins a strategic shift to an asset-lighter model, expected to improve capital efficiency and margins (Evotec)
Group revenues fell 5% to €371.2 m in H1 2025, with the core Discovery & Preclinical Development segment down 11% due to soft market conditions (Evotec)
Adjusted Group EBITDA remained negative at €(1.9) m in H1 2025, underscoring ongoing challenges in achieving profitability in the base business (Evotec)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Evotec News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.2B as of September 15, 2025.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of September 15, 2025.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.